Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial

202424 citationsJournal Articlehybrid Open Access

Authors

At week 52 of the PaTHway trial, TransCon PTH showed sustained efficacy, safety, and tolerability in adults with hypoparathyroidism.

Good health and well-being

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 110, Issue 4, pp. 951-960

Field-Weighted Citation Impact: 13.75